Roche(US:RHHBY) Cai Jing Wang·2026-01-09 08:22Core Viewpoint - Yilian Bio has entered into a new exclusive licensing agreement with Roche to jointly advance the development and commercialization of the candidate innovative antibody-drug conjugate (ADC) YL201 targeting B7H3 for various solid tumor indications [1] Group 1: Licensing Agreement Details - Under the terms of the agreement, Yilian Bio grants Roche exclusive rights to develop, manufacture, and commercialize the YL201 project globally, excluding mainland China, Hong Kong, and Macau [1] - Yilian Bio will receive an upfront payment of $570 million and milestone payments, along with additional payments based on development, registration, and commercialization milestones, as well as tiered royalties based on net sales after YL201 is approved for sale overseas [1] Group 2: Collaboration Background - This exclusive licensing agreement builds on the successful collaboration initiated in January 2024 regarding the YL211 (c-MetADC) project [1] - The partnership aims to leverage the strengths of both companies to accelerate the registration process of the YL201 project globally [1] Group 3: Commitment to Innovation - Both Yilian Bio and Roche are committed to scientific innovation and patient welfare, aiming to make this promising innovative therapy available to patients as soon as possible [1]